MX9801967A - Tetrahidroquinolinas como antagonistas de los aminoacidos excitadores (nmda). - Google Patents

Tetrahidroquinolinas como antagonistas de los aminoacidos excitadores (nmda).

Info

Publication number
MX9801967A
MX9801967A MX9801967A MX9801967A MX9801967A MX 9801967 A MX9801967 A MX 9801967A MX 9801967 A MX9801967 A MX 9801967A MX 9801967 A MX9801967 A MX 9801967A MX 9801967 A MX9801967 A MX 9801967A
Authority
MX
Mexico
Prior art keywords
tetrahydroquinolines
nmda antagonists
antagonists
salt
compounds
Prior art date
Application number
MX9801967A
Other languages
English (en)
Inventor
Romano Di Fabio
Simone Giacobbe
Barbara Bertani
Fabrizio Micheli
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9519893.3A external-priority patent/GB9519893D0/en
Priority claimed from GBGB9617306.7A external-priority patent/GB9617306D0/en
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of MX9801967A publication Critical patent/MX9801967A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen los compuestos de la formula (I): o una sal, un éster lábil metabolicamente del mismo, procesa para la preparacion de los mismos y su uso como antagonistas de los aminoácidos excitadores.
MX9801967A 1995-09-29 1998-03-12 Tetrahidroquinolinas como antagonistas de los aminoacidos excitadores (nmda). MX9801967A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9519893.3A GB9519893D0 (en) 1995-09-29 1995-09-29 Heterocyclic compounds
GBGB9617306.7A GB9617306D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
MX9801967A true MX9801967A (es) 1998-08-30

Family

ID=26307841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9801967A MX9801967A (es) 1995-09-29 1998-03-12 Tetrahidroquinolinas como antagonistas de los aminoacidos excitadores (nmda).

Country Status (29)

Country Link
US (1) US5977136A (es)
EP (1) EP0854867B1 (es)
JP (1) JP4108123B2 (es)
KR (1) KR100464895B1 (es)
CN (1) CN1130346C (es)
AP (1) AP876A (es)
AR (1) AR005233A1 (es)
AT (1) ATE221520T1 (es)
AU (1) AU708148B2 (es)
BR (1) BR9610733A (es)
CA (1) CA2232509A1 (es)
CZ (1) CZ292379B6 (es)
DE (1) DE69622731T2 (es)
DK (1) DK0854867T3 (es)
EA (1) EA000875B1 (es)
ES (1) ES2180799T3 (es)
HK (1) HK1009133A1 (es)
HU (1) HUP9900040A3 (es)
IL (1) IL123322A0 (es)
IS (1) IS4677A (es)
MX (1) MX9801967A (es)
NO (1) NO310355B1 (es)
NZ (1) NZ319596A (es)
PL (1) PL186781B1 (es)
PT (1) PT854867E (es)
SI (1) SI0854867T1 (es)
TR (1) TR199800531T1 (es)
TW (1) TW460465B (es)
WO (1) WO1997012870A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
TW555757B (en) * 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
AU5194999A (en) * 1998-08-07 2000-02-28 Takeda Chemical Industries Ltd. Benzothiepin derivatives, process for the preparation of the same and uses thereof
GB9929037D0 (en) 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
US7307075B2 (en) * 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
DE10236910A1 (de) * 2002-08-12 2004-03-11 Grünenthal GmbH Substituierte 1,2,3,4-Tetrahydrochinolinderivate
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
KR101136183B1 (ko) 2005-07-22 2012-04-17 모찌다 세이야쿠 가부시끼가이샤 신규 헤테로시클리덴 아세트아미드 유도체
BRPI0909105A2 (pt) * 2008-03-05 2015-08-25 Boehringer Ingelheim Int Derivados de piridina tricíclicos, composição farmacêutica e uso dos mesmos, bem como processos para preparar os ditos compostos e a dita composição farmacêutica
EP2286808A1 (en) * 2009-08-18 2011-02-23 Rheinische Friedrich-Wilhelms Universität Cytohesin inhibitors
CN102762554A (zh) 2010-02-16 2012-10-31 辉瑞大药厂 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇
MX2012009149A (es) 2010-02-19 2012-09-28 Boehringer Ingelheim Int Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion.
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2016114655A1 (en) * 2015-01-12 2016-07-21 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
WO2017065602A1 (en) * 2015-10-13 2017-04-20 Ry Pharma B.V. Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders

Also Published As

Publication number Publication date
CN1130346C (zh) 2003-12-10
ATE221520T1 (de) 2002-08-15
WO1997012870A1 (en) 1997-04-10
DE69622731T2 (de) 2003-02-20
JP4108123B2 (ja) 2008-06-25
PT854867E (pt) 2002-12-31
NO981396D0 (no) 1998-03-27
KR100464895B1 (ko) 2005-05-16
DE69622731D1 (de) 2002-09-05
CZ94098A3 (cs) 1998-07-15
AU7214896A (en) 1997-04-28
PL325966A1 (en) 1998-08-17
AU708148B2 (en) 1999-07-29
EP0854867B1 (en) 2002-07-31
JPH11512728A (ja) 1999-11-02
AP876A (en) 2000-09-27
EA000875B1 (ru) 2000-06-26
KR19990063850A (ko) 1999-07-26
CA2232509A1 (en) 1997-04-10
NZ319596A (en) 1999-09-29
AR005233A1 (es) 1999-04-28
BR9610733A (pt) 1999-07-13
HUP9900040A2 (hu) 1999-04-28
SI0854867T1 (en) 2003-02-28
NO981396L (no) 1998-05-27
CN1202887A (zh) 1998-12-23
NO310355B1 (no) 2001-06-25
HK1009133A1 (en) 1999-05-28
TR199800531T1 (xx) 1998-06-22
DK0854867T3 (da) 2002-12-02
IS4677A (is) 1998-02-27
EA199800230A1 (ru) 1998-10-29
ES2180799T3 (es) 2003-02-16
HUP9900040A3 (en) 2001-01-29
US5977136A (en) 1999-11-02
IL123322A0 (en) 1998-09-24
TW460465B (en) 2001-10-21
EP0854867A1 (en) 1998-07-29
PL186781B1 (pl) 2004-02-27
AP9801212A0 (en) 1998-03-31
CZ292379B6 (cs) 2003-09-17

Similar Documents

Publication Publication Date Title
TW334436B (en) Antiparasitic marcfortines and paraherquamides
MX9801967A (es) Tetrahidroquinolinas como antagonistas de los aminoacidos excitadores (nmda).
EP0992501A3 (en) Pyridonecarboxylic acid derivatives as antibacterial agents
CA2086914A1 (en) Quinolone-and naphthyridone-carboxylic acid derivatives
EP0271287A3 (en) Quinoline dioic acids and amides
HK1026909A1 (en) Substituted phenyl derivatives, their preparation and use
AU3363993A (en) Amino acid derivatives as PAF antagonists
MY118828A (en) Substituted amino compounds and their use as substances having an analgesic effect
AU5780890A (en) Tetrazole excitatory amino acid receptor antagonists
CA2087091A1 (en) Excitatory amino acid antagonists
PL316870A1 (en) Derivatives of 5-heterocyclo 1,5-benzodiazepine
MY117934A (en) Process for the preparation of n-methyl-3-(1-methyl-4- piperidinyl)-1h-indole-5-ethanesulphonamide
CA2266556A1 (en) Nmda (n-methyl-d-aspartate) antagonists
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
AU4770400A (en) Fused polycyclic amino acids as pharmaceutical agents
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
HU9403653D0 (en) New pharmaceutical use of 1,2,3,4,4a,5,10,10a-octahydro-benzo(g) quinoline derivatives
MY114693A (en) Substituted benzenesulfonylureas and thioureas,processes for their preparation,their use for the production of pharmaceutical preparations, and pharmaceutical preparation containing them
CA2018461A1 (en) Novel polypeptides and their use
MY122040A (en) 4 substituted carboxy tetrahydroquinoline derivatives
DE3867039D1 (de) Vincristin enthaltendes produkt.
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation
MX9606009A (es) Uso de 8,9-deshidroestrona como un antioxidante.
IE840831L (en) 1,4-dihydropyridine derivatives
AU1459192A (en) Aminoacyl derivatives of gem-diphosphonic acids, a process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees